#MRSA Antibiotics market forecast | Explore Tumblr Posts and Blogs

priyanshisingh · 4 months

Text

Nosocomial Infection Treatment Market Insights: Comprehensive Global Forecast (2023-2032)

The global demand for nosocomial infection treatment was valued at USD 30154.56 Million in 2023 and is expected to reach USD 35720.76 Million in 2032, growing at a CAGR of 1.90% between 2024 and 2032.

The nosocomial infection treatment market is experiencing significant growth driven by the increasing incidence of hospital-acquired infections (HAIs), advancements in diagnostic techniques, and the development of new and effective treatment options. Nosocomial infections, also known as healthcare-associated infections, are infections that patients acquire while receiving treatment for other conditions within a healthcare setting. Common HAIs include infections like methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), urinary tract infections, pneumonia, and surgical site infections. The rising prevalence of these infections is attributed to factors such as the growing number of surgical procedures, prolonged hospital stays, the increasing use of invasive devices like catheters and ventilators, and the spread of antibiotic-resistant bacteria.

Advancements in diagnostic technologies are playing a crucial role in the early detection and management of nosocomial infections. Rapid diagnostic tests and molecular diagnostic tools have significantly improved the ability to quickly identify pathogens, allowing for timely and targeted treatment. This is particularly important in controlling the spread of infections within healthcare facilities and improving patient outcomes. Additionally, the development of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies has enabled precise identification of microbial strains, aiding in the selection of appropriate antimicrobial therapies.

The treatment landscape for nosocomial infections is evolving with the introduction of new antibiotics, antifungals, and antiviral agents. The growing problem of antibiotic resistance has spurred research and development efforts to discover novel antimicrobial agents that are effective against resistant strains. Pharmaceutical companies are also exploring combination therapies that enhance the efficacy of existing antibiotics and reduce the risk of resistance development. Immunotherapy and bacteriophage therapy are emerging as promising alternatives, offering targeted approaches to infection treatment.

The key findings of the study on the nosocomial infection treatment market highlight the current state of the market, its driving factors, challenges, and future prospects. These findings provide valuable insights into the dynamics of the market and its growth trajectory. Here are the key findings:

1. Rising Incidence of Nosocomial Infections

The study reveals a significant increase in the prevalence of hospital-acquired infections (HAIs) globally. Factors contributing to this rise include the growing number of surgical procedures, increased use of invasive devices, longer hospital stays, and the spread of antibiotic-resistant bacteria. Common HAIs such as MRSA, C. difficile, urinary tract infections, pneumonia, and surgical site infections are major concerns for healthcare facilities.

2. Advancements in Diagnostic Technologies

Rapid advancements in diagnostic technologies are enhancing the early detection and precise identification of pathogens causing HAIs. The development and adoption of rapid diagnostic tests, molecular diagnostics, next-generation sequencing (NGS), and polymerase chain reaction (PCR) techniques are improving the speed and accuracy of diagnosis. This allows for timely and targeted treatment, ultimately improving patient outcomes and controlling the spread of infections.

3. Emergence of Novel Antimicrobial Agents

The growing problem of antibiotic resistance is driving research and development efforts to discover new antimicrobial agents. Pharmaceutical companies are focusing on the development of novel antibiotics, antifungals, and antiviral agents that are effective against resistant strains. Combination therapies, immunotherapy, and bacteriophage therapy are emerging as promising treatment approaches, offering targeted solutions to combat resistant infections.

4. Importance of Infection Control Measures

The study emphasizes the critical role of infection control measures in reducing the incidence of HAIs. Healthcare facilities are increasingly adopting stringent hygiene practices, antimicrobial stewardship programs, and advanced sterilization and disinfection technologies. The implementation of infection control guidelines and protocols by regulatory bodies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) has further bolstered efforts to prevent HAIs.

5. Aging Population and Chronic Diseases

The growing aging population and the rise in chronic diseases such as diabetes and cancer contribute to the increased risk of HAIs. Older adults and individuals with chronic conditions often require frequent hospital visits and medical procedures, making them more susceptible to infections. This demographic trend underscores the need for effective nosocomial infection treatments and preventive measures.

6. Regional Variations

The study identifies regional variations in the nosocomial infection treatment market. North America and Europe dominate the market due to their advanced healthcare infrastructure, high healthcare expenditure, and strong regulatory frameworks. The Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare investments, rising awareness about infection control, and the growing burden of HAIs in countries like China and India. Latin America and the Middle East and Africa are gradually improving their healthcare systems, focusing on enhancing infection control measures.

7. Competitive Landscape

The market is highly competitive, with major players focusing on strategic collaborations, mergers and acquisitions, and product innovations to strengthen their market positions. Leading companies such as Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, and GlaxoSmithKline plc are continuously investing in R&D to develop new antimicrobial agents and improve existing treatments. Emerging players are also contributing to market growth with innovative solutions and targeted therapies.

8. Future Prospects

The nosocomial infection treatment market is poised for robust growth, driven by the rising prevalence of HAIs, advancements in diagnostic and therapeutic technologies, and increased efforts towards infection prevention and control. The continuous evolution of treatment options, the implementation of stringent infection control measures, and the growing adoption of advanced technologies will be crucial in addressing the challenges posed by nosocomial infections and improving patient care outcomes in healthcare settings.

Key Players:

3M Company

Abbott Laboratories

Advanced Sterilization Products Services Inc. (ASP)

Becton, Dickinson and Company (BD)

Belimed AG

BioMérieux SA

Cantel Medical Corp.

Getinge Group

Johnson & Johnson

Merck & Co., Inc.

Pfizer Inc.

Roche Diagnostics Corporation

Stryker Corporation

Thermo Fisher Scientific Inc.

Steris Corporation

Zimmer Biomet Holdings, Inc.

Ansell Limited

Molnlycke Health Care AB

Cantel Medical Corp.

More About Report- https://www.credenceresearch.com/report/nosocomial-infection-treatment-market

The nosocomial infection treatment market exhibits distinct regional characteristics, driven by variations in healthcare infrastructure, regulatory frameworks, awareness levels, and prevalence of hospital-acquired infections (HAIs). Here's an overview of the regional insights:

North America

Key Characteristics:

Advanced Healthcare Infrastructure: North America, particularly the United States, boasts a highly advanced healthcare system with well-equipped hospitals and clinics. This supports the adoption of advanced diagnostic and treatment technologies for nosocomial infections.

High Healthcare Expenditure: The region's significant healthcare spending enables substantial investment in infection control measures, antimicrobial research, and the implementation of advanced treatment protocols.

Strong Regulatory Framework: Agencies like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) enforce stringent guidelines and regulations for infection control and the approval of new treatments.

Research and Development Hub: North America is a major hub for pharmaceutical and biotechnology research, leading to the continuous development of novel antimicrobial agents and diagnostic tools.

Europe

Key Characteristics:

Robust Infection Control Policies: Europe has established comprehensive infection control policies and guidelines, supported by organizations such as the European Centre for Disease Prevention and Control (ECDC).

High Awareness and Education: There is a high level of awareness and education regarding HAIs among healthcare professionals and the general public, promoting adherence to hygiene and infection control practices.

Government Initiatives: European governments actively invest in healthcare infrastructure and infection control programs, facilitating better management and treatment of nosocomial infections.

Collaborative Research: Europe benefits from collaborative research initiatives and funding from the European Union, driving advancements in diagnostics and treatments for HAIs.

Asia-Pacific

Key Characteristics:

Rapidly Developing Healthcare Infrastructure: The Asia-Pacific region is experiencing rapid growth in healthcare infrastructure, particularly in countries like China, India, and Japan. This expansion supports the increased adoption of advanced medical technologies.

Rising Prevalence of HAIs: The growing burden of HAIs in densely populated countries necessitates effective infection control and treatment strategies.

Increasing Healthcare Investments: Governments in the region are investing heavily in healthcare improvements, including infection prevention and control measures.

Awareness and Education Campaigns: Efforts to raise awareness about the importance of infection control are gaining momentum, leading to better implementation of hygiene practices and protocols.

Latin America

Key Characteristics:

Developing Healthcare Systems: Latin American countries are working towards improving their healthcare systems, with a focus on enhancing infection control measures and access to advanced treatments.

High Burden of HAIs: The prevalence of HAIs is relatively high, driving the need for effective diagnostic and therapeutic solutions.

Government and NGO Initiatives: Both government bodies and non-governmental organizations (NGOs) are playing active roles in promoting infection control and funding healthcare improvements.

Middle East and Africa

Key Characteristics:

Emerging Healthcare Infrastructure: The region is witnessing gradual improvements in healthcare infrastructure, with a focus on modernizing hospitals and clinics.

High Infection Rates: The high incidence of HAIs, coupled with limited resources, presents significant challenges in infection control and treatment.

Government Efforts: Governments are increasingly prioritizing healthcare investments and infection control programs to address the rising burden of HAIs.

International Support: International organizations and partnerships are providing support for healthcare improvements and infection control initiatives.

Segmentation:

By Type of infection

Urinary Tract Infections (UTIs)

Surgical Site Infections (SSIs)

Pneumonia

Bloodstream Infections

Gastrointestinal Infections

Skin and Soft Tissue Infections

By Treatment Type

Antibiotics

Antifungal Agents

Antiviral Drugs

Surgical Interventions

Supportive Care

By End User

Hospitals

Long-Term Care Facilities

Ambulatory Surgical Centers

Clinics and Outpatient Settings

Home Healthcare

Browse the full report – https://www.credenceresearch.com/report/nosocomial-infection-treatment-market

Browse Our Blog: https://www.linkedin.com/pulse/nosocomial-infection-treatment-market-pmq0f

Phone: +91 6232 49 3207

Email: [email protected]

Website: https://www.credenceresearch.com

0 notes

delicatemagazinedreamer · 1 year

Text

Antimicrobial Therapeutics Market Is Estimated To Witness High Growth Owing To Increasing Resistance to Antibiotics

The global Antimicrobial Therapeutics Market is estimated to be valued at US$ 219.80 billion in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Antimicrobial Therapeutics market comprises various pharmaceutical products that are used to treat microbial infections. These therapeutics play a crucial role in managing and treating diseases caused by bacteria, viruses, fungi, and parasites. The major advantages of antimicrobial therapeutics include their ability to effectively target specific pathogens and their potential for minimal side effects. The need for these products arises from the increasing prevalence of antimicrobial resistance, which has become a global health concern. Antimicrobial therapeutics are essential for combating the growing resistance to antibiotics and ensuring effective treatment options. Market Key Trends: One key trend driving the growth of the Antimicrobial Therapeutics market is the increasing resistance to antibiotics. Over the years, microbes have developed resistance to commonly used antibiotics, rendering them ineffective in treating infections. This has led to the need for alternative antimicrobial therapeutics that can target drug-resistant pathogens. For example, the emergence of antibiotic-resistant strains of bacteria such as Methicillin-Resistant Staphylococcus Aureus (MRSA) has created a demand for novel therapeutics such as antimicrobial peptides, which have shown efficacy against resistant strains. This trend presents significant opportunities for market players to develop innovative therapeutics to address the challenge of antimicrobial resistance. PEST Analysis: Political: Governments worldwide have taken initiatives to combat antimicrobial resistance through policies and regulations. For instance, the World Health Organization developed a Global Action Plan on Antimicrobial Resistance to provide guidelines for countries to mitigate the risks associated with drug-resistant pathogens. Economic: The Antimicrobial Therapeutics market is driven by both the public and private sector investments. Governments and healthcare organizations are allocating funds to support research and development activities for developing new antimicrobial therapeutics. Moreover, the rising healthcare expenditure and the increasing demand for effective treatment options are expected to drive market growth. Key Takeaways: 1) Market size related content: The global Antimicrobial Therapeutics Market Share is expected to witness high growth, exhibiting a CAGR of 4.8% over the forecast period. This growth can be attributed to increasing resistance to antibiotics, which has created a demand for alternative therapeutics. For example, companies like Pfizer Inc., Johnson & Johnson, and GlaxoSmithKline plc are investing in research and development activities to develop novel antimicrobial products. 2) Regional analysis related content: North America is expected to dominate the Antimicrobial Therapeutics market due to the presence of major pharmaceutical companies and a well-established healthcare infrastructure. However, Asia Pacific is anticipated to be the fastest-growing region during the forecast period. This can be attributed to increasing awareness about antimicrobial resistance, rising healthcare expenditure, and growing investments in research and development activities. 3) Key players related content: Key players operating in the global Antimicrobial Therapeutics market include Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Roche Holding AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, and Mylan N.V. These companies are focusing on strategic partnerships, mergers and acquisitions, and investments in research and development to strengthen their market position and develop innovative antimicrobial therapeutics.

0 notes

trendingresearchreports · 2 years

Text

0 notes

marketresearchhealthcarefuture · 3 years

Text

Retropharyngeal Abscess Market Research Report Analysis and Forecast to 2027

Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4922

The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.

The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.

Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.

Key Players

Merck KGaA,

Johnson & Johnson,

AstraZeneca plc,

Sanofi S.A.,

Pfizer,

Mylan N.V,

Novartis AG,

Teva pharmaceutical company,

GlaxoSmithKline plc.

Segments

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Browse Complete 85 Pages Premium Research Report Enabled with 66 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

1 note · View note

abrreports-blog · 4 years

Text

MRSA Antibiotics Market Key Trends, Drivers, Growth Opportunities, and 2025 Industry Chain Structure Analysis

The research study MRSA Antibiotics market 2020 launched by ABRReports.com provides the detailed analysis of current market status, investment plans, production and consumption, price trends, leading key companies, growth drivers and future prospect. The base year considered for the study is 2019, and the market size is projected from 2020 to 2025

Get the Sample Copy of MRSA Antibiotics market report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

The segmentation of MRSA Antibiotics study as mentioned below:

By Market Players:

Pfizer, Sanofi, Novartis

By Application

Adults, ChildrenVancomycin, Teicoplanin, Linezolid, Cubicin, Others

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc. The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2014 to 2019 and forecast data from 2020 to 2025.

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

The key objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Purchase the research study @ https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-mrsa-antibiotics-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

Key pointers of the Table of Contents:

Chapter 1 Industry Overview

Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis

Chapter 3 Production Market Analysis

Chapter 4 Sales Market Analysis

Chapter 5 Consumption Market Analysis

Chapter 6 Production, Sales and Consumption Market Comparison Analysis

Chapter 7 Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 8 Marketing Channel Analysis

Chapter 9 Industry Chain Analysis

Chapter 10 Global and Regional Market Forecast

Chapter 11 Major Manufacturers Analysis

Chapter 12 New Project Investment Feasibility Analysis

Chapter 13 Conclusions

Continued…

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

Scott Harris

Sales Manager

Email ID: [email protected]

Phone No.: +1-561-448-7424

#MRSA Antibiotics market 2020 #MRSA Antibiotics market forecast #MRSA Antibiotics market insights #MRSA Antibiotics market price

0 notes

neharoy11 · 4 years

Link

The global MRSA Antibiotics market size is estimated at xxx million USD with a CAGR xx% from 2015-2019 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of MRSA Antibiotics by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

#MRSA Antibiotics Market #MRSA Antibiotics Market trends #MRSA Antibiotics Market share #MRSA Antibiotics Market size #MRSA Antibiotics Market analysis #MRSA Antibiotics Market overview #MRSA Antibiotics Market forecast #MRSA Antibiotics Market growth #MRSA Antibiotics

0 notes

vijayanger12 · 2 years

Text

The global VRE and MRSA Antibiotic market size is estimated to be worth US$ 4055.6 million in 2021 and is forecast to a readjusted size of US$ 5354.3 million by 2030 with a CAGR of 4.0% during the forecast period 2022-2030.

#VRE and MRSA Antibiotic market size

0 notes

vicky8588 · 3 years

Text

Global Skin and Soft Tissue Infections Market Size Share and Industry Outlook to 2028

Market Overview

The Global Skin and Soft Tissue Infections Market are expected to grow at a high CAGR during the forecasting period (2021-2028).

Skin and Soft Tissue Infections (SSTI) result from the microbial invasion of the surface and its supporting structures.

They encompass a broad spectrum of inflammatory diseases of the skin, subcutis, fascia, and muscles.

SSTIs are the second most common infection encountered in hospitals.

SSTIs can lead to complications with significant morbidity, including hospitalization, surgical procedures, bacteremia, and even death.

Download free sample: https://www.datamintelligence.com/download-sample/skin-and-soft-tissue-infections-market

Market Growth

The global Skin and Soft Tissue Infections market is estimated to show significant growth.

Major market drivers include raising some MRSA infections and new product developments.

Resistance to new strains of infectious bacteria is the most critical factor affecting the SSTI drug market, in both community and hospital settings.

Market Segmentation

Global Skin and Soft Tissue Infections market report segments the market by drug class, end-user, and by region.

Based on the medications used for its treatment, the market includes antibiotics and anti-fungal agents.

Antibiotics further include beta-lactam and macrolides.

Market Geographical Share

The skin and soft tissue infections market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

North America will dominate the market owing to high the incidence of infections.

SSTIs account for more than 14 million physician office visits each year in the US, as well as emergency department visits and hospitalizations.

Market Scope of the report

The report also profiles the following companies of the Skin and Soft Tissue Infections market – Cubist Pharmaceuticals, Inc., Wockhardt Limited, Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and Melinta Therapeutics Inc.

View full report: https://www.datamintelligence.com/research-report/skin-and-soft-tissue-infections-market

By Drug Type

l Antibiotics

l Anti-fungal agents

By End-User

l Outpatient clinics

l Emergency department

l Inpatient ward

By Region

l Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

l Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

l North America (The USA, Canada, Mexico)

l South America (Brazil, Argentina, Rest of South America)

l Rest of the World

Trending Topics

Interferons Market

Anti-malarial Drugs Market

Invasive Fungal Infection Market

#skin and soft tissue infections market skin and soft tissue infections market 2028 skin and soft tissue infections industry skin and soft ti

0 notes

myabhijitr · 3 years

Text

Informative Report On (COVID-19 Updates) Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is Generating Revenue of US$ 1,327.9 Million by 2027

The COVID-19 infection has expanded to over 100 nations since its breakout in December 2019, prompting the World Health Organization to designate it a public health crisis. According to a study published by the World Health Organization, coronavirus illness (COVID-19) has affected over 45 million people globally as of October 30, 2020. Due to the rising incidence of COVID-19, major companies in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are focused on the research and development of new funds to enhance and counteract COVID-19’s effects. The COVID-19 pandemic has had a significant influence on the worldwide economy and, as a result, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market was also affected. Quarantines, travel restrictions, and social distancing measures are all expected to result in a significant drop in corporate and consumer expenditure until the third quarter of 2020.

Request for Analysis of COVID-19 Impact on Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market – https://www.coherentmarketinsights.com/insight/request-sample/1538

Overview

Antibiotic-resistant forms of the bacterium staphylococcus aureus produce methicillin-resistant staphylococcus aureus (MRSA). Based on the route of infection, methicillin-resistant Staphylococcus aureus (MRSA) can be classified into two types: hospital-associated MRSA infections (HA-MRSA) and community-associated MRSA infections (CA-MRSA). Invasive treatments, such as surgeries, intravenous tubing, and skin-to-skin contact, are the most common causes of this illness. MRSA medicines are used to treat or prevent infections caused by Methicillin-resistant Staphylococcus aureus. For the treatment of infections caused by MRSA, a variety of antibiotic medicines are available on the market.

In 2020, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market is anticipated to be worth US$ 984.6 million, growing at a CAGR of 4.4 percent during the forecast period (2020-2027).

Drivers

During the forecast period, the global methicillin-resistant staphylococcus aureus (MRSA) drugs market is projected to expand due to an increase in new launches and clearances.

Infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) bacteria are becoming more common, causing public health concerns. Companies are concentrating on product research and releases for the diagnosis of Methicillin-resistant Staphylococcus aureus (MRSA), which is impelling the global Methicillin-resistant Staphylococcus aureus (MRSA) drugs market. NUZYRA (omadacycline) was introduced in the U.S. by Paratek Pharmaceuticals, Inc. in February 2019. The antibiotic is offered as an intravenous and oral once-daily dose. It was created to combat tetracycline resistance and work against a wide range of bacteria, particularly gram-positive, gram-negative, atypicals, and other drug-resistant species.

Request PDF Brochure Report – https://www.coherentmarketinsights.com/insight/request-pdf/1538

In addition, one of the crucial factors driving the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is the implementation of inorganic business expansion such as mergers, acquisitions, and partnerships by main players. In March 2019, Melinta Therapeutics signed an exclusive license, supply, and supply chain contract with Hikma Pharmaceuticals.

0 notes

healthcare-market · 3 years

Text

Impact of COVID-19 on Antimicrobial Susceptibility Test Market

Transparency Market Research (TMR) has published a new report titled, ‘Antimicrobial Susceptibility Test Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Antimicrobial Susceptibility Test market was valued at US$ 2,770.9 Mn in 2018 and is projected to expand at a CAGR of 4.9% from 2019 to 2027.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31508

Overview

· Antimicrobial susceptibility test can be defined as a procedure employed for determining which antimicrobials inhibit the growth of the bacteria or fungi which cause specific infections. The results from this test aid the healthcare practitioner in determining the drugs effective for the treatment of patient’s infection.

· There is a drastic increase in the antibacterial – resistance bacterial strains over a decade, this has led to few antibiotics which can control the infection, hence increasing the cost of treatment. In South East Asia the prevalence of infections due to antibiotic resistance is very high. This is due to unhygienic sanitation habits and socioeconomic barriers. In South East Asia, WHO has identified 7 bacteria with high antibiotic resistance, amongst them Enterobacteriaceae and meticillin resistant Staphylococcus aureus (MRSA) are of greatest concern, as fatal or high infections are caused by these bacteria. Hence it necessitates the need for antimicrobial susceptibility testing, contributing to the growth of the market.

· North America dominated the global antimicrobial susceptibility test market in 2018 and the trend is anticipated to continue during the forecast period. The growth of the North America antimicrobial susceptibility test market is attributed with increasing incidence of infectious diseases in the U.S. and Canada are important factors contributing for the growth of the market. According to CDC, in the U.S. approximately, 2 million people are infected with bacteria that are resistant to antibiotics and at least 23,000 people die each year as a direct result of these infections.

· Asia Pacific is likely to be a highly lucrative market for antimicrobial susceptibility test and it is expected to expand at a high CAGR during the forecast period. The growth of the market in the region can be attributed to increasing incidence of infectious diseases and increasing antibiotic resistance. According to NCBI, resistance to fluoroquinolones among invasive Salmonella Typhi isolates in India increased from 8% in 2008 to 28% in 2014.

Request for Analysis of COVID19 Impact on Antimicrobial Susceptibility Test Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31508

Infection Control in Health Care Settings to Drive Market

· Increase in incidence of bacterial infection in intensive care with no effective treatment is likely to drive demand for newer antibacterial drugs

· Patients with serious infections such as severe pneumonia and patients with bacterial infection complications after major surgery are treated with antibacterial drugs to avoid infections, as delay in treatment will lead to a serious risk for the patient. Broader-spectrum antibacterial for such empirical treatments drive the need for newer antibacterial drugs.

· In most countries, approximately 20% of antibacterial drugs are used in hospitals and other health care facilities. Hospitals generate some of the most critical infections due to increased use of antibacterial drugs. This increases demand for newer broader spectrum antibacterial drugs aids in the growth of the antimicrobial susceptility test market.

Disk Diffusion Method Segment to Dominate Market

· Based on method, the global Antimicrobial Susceptibility Test market has been divided into broth dilution method, rapid automation method, disk diffusion method, gradient diffusion method, and molecular testing method. The disk diffusion method segment dominated the global Antimicrobial Susceptibility Test market in 2018 and the trend is projected to continue during the forecast period. The growth of the segment can be attributed to its wider usage in the detection of growth of bacterial colonies both on large scale and small scale.

Antibacterial Antimicrobial Susceptibility Test to be Highly Lucrative Segment

· In terms of test type, the global Antimicrobial Susceptibility Test market has been classified into antibacterial, antifungal, antiparasitics, and others.

· The antibacterial segment dominated the antimicrobial susceptibility test market in 2018 and is likely to remain dominant in the forecast period. Increasing incidence of bacterial infections will drive the growth of the segment. Centers for Disease Control and Prevention (CDC) has classified a number of bacteria as presenting urgent, serious, and concerning threats, many of which are already responsible for placing a substantial clinical and financial burden on the U.S. health care system, patients, and their families.

Buy now Antimicrobial Susceptibility Test Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=31508&ltype=S

North America to Dominate Global Market

· In terms of region, the global antimicrobial susceptibility test market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global antimicrobial susceptibility test market in 2018, followed by Europe.

· North America accounted for major share of the global antimicrobial susceptibility test market in 2018, owing to increase in incidence of infectious diseases, rise in resistance to antibiotics, and growth in investment of key players in developing new treatment options are factors driving the antimicrobial susceptibility test market in these regions

· The antimicrobial susceptibility test market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027. This can be attributed to rapid economic growth in developing economies such as India, China, Indonesia, Vietnam, South Korea, and the Philippines. Rising investment by key players in research, increasing government spending, and high prevalence of diseases in the region contributes to the growth of the antimicrobial susceptibility test market.

Competitive Landscape

· The global antimicrobial susceptibility test market is fragmented in terms of number of players. Key players in the global market include Bio-Rad Laboratories, Inc., Beckman Coulter, Inc. (Subsidiary of Danaher Corporation), Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Conda, Creative Diagnostics, HiMedia Laboratories, Alifax Holding S.p.A., and Biotron Healthcare, among others.

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/topical-oral-medications-core-of-acne-scar-treatment-market-growth-trajectory--tmrs-study-301341979.html

https://www.prnewswire.com/news-releases/increase-in-focus-on-use-of-advanced-technology-for-drug-development-research-activities-to-drive-global-biosimulation-market-finds-tmr-301348168.html

https://www.prnewswire.com/news-releases/rise-in-use-of-technologically-advanced-products-in-orthopedic-disease-treatment-creates-lucrative-avenues-for-orthopedic-devices-market-opines-tmr-301355874.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

0 notes

blueweave01 · 3 years

Text

Global Antimicrobial Susceptibility Testing Market Proliferating & Projected to Reach Worth USD 4.70 Billion by 2027

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global antimicrobial susceptibility testing market was worth USD 3.19 billion in 2020 and is further projected to reach USD 4.70 billion by 2027. The emergence of multidrug-resistant microbial strains like MRSA, Klebsiella pneumonia, Acinetobacter baumanii, etc., is the primary cause of the growth of the global antimicrobial susceptibility market. Apart from that, the growing cases of infectious diseases across the globe, coupled with increasing government funding and initiatives, and automated rapid AST (Antimicrobial susceptibility testing) methods are some of the key factors aiding the rapid growth of the global antimicrobial susceptibility testing market.

Growing cases of infectious diseases acting as a catalyst for the global antimicrobial susceptibility testing market

According to Columbia University's Stephen Morse, emerging infections are infections that are rapidly expanding in frequency or geographic range, such as HIV/AIDS, severe acute respiratory syndrome (SARS), Ebola hemorrhagic fever, and Nipah virus encephalitis. The emergence of new infections and microbial strains into a host population and its establishment within the said population is mainly due to the vast and highly uncharacterized “zoonotic pool” of possible human pathogens as well as the increasing opportunities for infection caused by ecological upheaval and globalization.

Human activity, however, is making the transition very easy by creating efficient pathways for pathogen transmission around the globe. For example, the anti-vaxxers movement in the U.S. for flu vaccination led to a decrease in the vaccination rate. As a result, the vaccination rate in 2018 was 37.1% which was 6.2% lower than the vaccination rate in 2017. Due to such emergence of infectious diseases caused by human activities, AST has become imperative, thus aiding in the growth of the global antimicrobial susceptibility testing market.

Increasing prevalence of multidrug-resistant microbial strains making antimicrobial susceptibility testing an imperative process

Antimicrobial Agents (AMA) are the secondary metabolites produced by microorganisms that selectively suppress the growth or kill other microorganisms at a very low concentration with minimum injury to the host cell. Antibiotic-resistant bacteria are an essentially inevitable outcome of the extensive use of antimicrobial agents. The discovery, commercialization, and widespread administration of antimicrobial substances ushered in a new era in contemporary medicine, altering the therapeutic paradigm for treating infections. Unfortunately, the successful outcomes of critically sick patients have been jeopardized due to a considerable increase in antibiotic resistance among prevalent bacterial infections. As a result, antibiotic resistance is one of the three most serious public health problems of the 21st century, according to the World Health Organization.

The emergence of multidrug-resistant organisms in the hospital environment and community settings suggests that reservoirs of antibiotic-resistant bacteria are present even outside the hospital. The answer is "survival of the fittest," which explains the enormous genetic flexibility of bacterial pathogens that stimulate specialized reactions, culminating in mutational adaptations. Resistance to practically all antibiotics currently available in clinical practice results from the acquisition of genetic material or the modification of gene expression. Therefore, to prevent paradoxical worsening of the patient's condition due to over-medication or under-medication, antimicrobial susceptibility testing has become imperative to treat microbial infection, leading to the growth of the global antimicrobial susceptibility testing market.

Global antimicrobial susceptibility testing market by end-user

Based on the end-user, the global antimicrobial susceptibility testing market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research & academic institutes, clinical research organizations (CROS). The hospitals segment hold the largest share in the global antibiotic susceptibility testing market as they are prominent end-users of antimicrobial susceptibility testing products. The large share of hospitals is also due to the growing prevalence of hospital-acquired infections, such as Hospital-Acquired Pneumonia and Ventilator Acquired Pneumonia. Furthermore, due to the presence of high-tech and well-equipped facilities and equipment, as well as highly trained/skilled technicians in diagnostic laboratories, as well as various endeavors by important players to provide efficient AST products to diagnostic laboratories, the diagnostic center segment is likely to witness exemplary growth during the forecast period.

Global antimicrobial susceptibility testing market by region

Based on region, the global antimicrobial susceptibility testing market is segmented into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. Out of these regions, North America has the largest share of the global antimicrobial susceptibility testing market. TNorth America’s dominance can be attributed to the growing investment in R&D to develop novel automated AST systems, technological advancements in antimicrobial susceptibility products, and increasing cases of infections like Lyme Disease and West Nile. On the other hand, the Asia Pacific antimicrobial susceptibility testing market is also growing owing to the increasing public health awareness, increasing population, and over-consumption of antibiotics.

Impact of COVID-19

With the outbreak of the COVID-19, major industries and businesses, as well as people's daily lives, have been disrupted. To curb the spread of the COVID-19 virus, almost every country had to impose nationwide lockdown and. Since the pandemic, hospitals have prioritized COVID-19 treatment; consequently, the usage of automated antimicrobial susceptibility testing technologies such as the Accelerate Pheno system, MicroScan WalkAway system, and Sensitive ARIS system has been drastically reduced. Additionally, the stringent government rules and regulations during the pandemic on new product launches and instrument approval also severely impacted the global antimicrobial susceptibility testing market.

Competitive Landscape

The global antimicrobial susceptibility testing market is thriving owing to the growing prevalence of infectious diseases, emergence of antimicrobial-resistant strains, and government initiatives. As a result, the market is attracting many key players. Some of the key players in the global antimicrobial susceptibility testing market are PML Microbiologicals Inc., BioMérieux SA, QuantaMatrix Inc., MP Biomedicals, InvivoGen, Biotron Ltd, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics Limited, Bio-Rad Laboratories, Inc., Merck KGaA, Accelerate Diagnostics, Inc., Liofilchem S.r.l., ZHUHAI DL BIOTECH Co., Ltd., ELITechGroup, Halifax S.r.l., Hi-Media Laboratories, Genefluidics, Inc., Creative Diagnostics, and other prominent players.

Don’t miss the business opportunity of the global antimicrobial susceptibility testing market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and statistics of the global antimicrobial susceptibility testing market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the global antimicrobial susceptibility testing market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

Blue Weave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost your business solution's performance. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are a promising digital MI solutions company providing agile assistance to make your business endeavors successful.

0 notes

marketresearchhealthcarefuture · 3 years

Text

Retropharyngeal Abscess Market Research Report Analysis and Forecast to 2027

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4922

Key Players

Merck KGaA,

Johnson & Johnson,

AstraZeneca plc,

Sanofi S.A.,

Pfizer,

Mylan N.V,

Novartis AG,

Teva pharmaceutical company,

GlaxoSmithKline plc.

Segments

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis

Browse Complete 85 Pages Premium Research Report Enabled with 66 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922

About US:

1 note · View note

healthcare-market · 3 years

Text

Antibiotic Susceptibility Testing Market Growth Trends, Current Demand, and Development Report

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31508

Overview

Request for Analysis of COVID19 Impact on Antimicrobial Susceptibility Test Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=31508

Infection Control in Health Care Settings to Drive Market

· Increase in incidence of bacterial infection in intensive care with no effective treatment is likely to drive demand for newer antibacterial drugs

Disk Diffusion Method Segment to Dominate Market

Antibacterial Antimicrobial Susceptibility Test to be Highly Lucrative Segment

· In terms of test type, the global Antimicrobial Susceptibility Test market has been classified into antibacterial, antifungal, antiparasitics, and others.

Buy now Antimicrobial Susceptibility Test Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=31508&ltype=S

North America to Dominate Global Market

Competitive Landscape

More Trending Reports by Transparency Market Research:

https://www.prnewswire.co.uk/news-releases/growth-in-older-population-drives-demand-opportunities-in-surgical-drainage-devices-market-tmr-879678955.html

https://www.prnewswire.com/news-releases/new-models-in-organoids-market-open-new-vistas-in-stem-cell-research-for-cancer-global-valuation-to-reach-us-12-8-bn-by-2030-tmr-301206242.html

About Us

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

#antibiotic susceptibility testing methods #automated antimicrobial susceptibility testing methods #antibiotic susceptibility testing disk diffusion method

0 notes